CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Organogenesis Holdings Inc. - ORGO CFD

3.30
18.71%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Organogenesis Holdings Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.78
Open* 2.62
1-Year Change* -0.38%
Day's Range* 2.62 - 3.32
52 wk Range 1.80-4.50
Average Volume (10 days) 2.12M
Average Volume (3 months) 18.65M
Market Cap 338.03M
P/E Ratio 26.17
Shares Outstanding 132.04M
Revenue 449.01M
EPS 0.10
Dividend (Yield %) N/A
Beta 1.41
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 3.30 0.57 20.88% 2.73 3.33 2.61
Dec 7, 2023 2.78 -0.01 -0.36% 2.79 2.84 2.74
Dec 6, 2023 2.83 0.12 4.43% 2.71 2.93 2.67
Dec 5, 2023 2.68 0.06 2.29% 2.62 2.68 2.61
Dec 4, 2023 2.71 0.11 4.23% 2.60 2.77 2.60
Dec 1, 2023 2.70 0.17 6.72% 2.53 2.70 2.46
Nov 30, 2023 2.53 -0.11 -4.17% 2.64 2.65 2.50
Nov 29, 2023 2.65 0.08 3.11% 2.57 2.69 2.57
Nov 28, 2023 2.59 0.05 1.97% 2.54 2.59 2.53
Nov 27, 2023 2.59 0.01 0.39% 2.58 2.60 2.51
Nov 24, 2023 2.56 0.00 0.00% 2.56 2.64 2.56
Nov 22, 2023 2.56 0.00 0.00% 2.56 2.66 2.53
Nov 21, 2023 2.53 -0.03 -1.17% 2.56 2.56 2.51
Nov 20, 2023 2.59 -0.03 -1.15% 2.62 2.65 2.55
Nov 17, 2023 2.62 0.07 2.75% 2.55 2.64 2.45
Nov 16, 2023 2.50 0.04 1.63% 2.46 2.54 2.44
Nov 15, 2023 2.49 -0.01 -0.40% 2.50 2.62 2.46
Nov 14, 2023 2.48 0.12 5.08% 2.36 2.50 2.36
Nov 13, 2023 2.29 0.16 7.51% 2.13 2.33 2.08
Nov 10, 2023 2.16 -0.04 -1.82% 2.20 2.33 2.06

Organogenesis Holdings Inc. Events

Time (UTC) Country Event
Wednesday, February 28, 2024

Time (UTC)

21:00

Country

US

Event

Q4 2023 Organogenesis Holdings Inc Earnings Release
Q4 2023 Organogenesis Holdings Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 450.893 468.059 338.298 260.981 193.449
Revenue 450.893 468.059 338.298 260.981 193.449
Total Operating Expense 428.589 397.024 309.352 292.697 247.1
Selling/General/Admin. Expenses, Total 283.808 250.2 204.193 200.088 161.961
Operating Income 22.304 71.035 28.946 -31.716 -53.651
Net Income Before Taxes 20.282 63.786 17.764 -38.559 -64.747
Net Income After Taxes 15.532 94.902 17.234 -38.709 -64.831
Net Income Before Extra. Items 15.532 94.902 17.234 -38.709 -64.831
Net Income 15.532 94.902 17.234 -38.709 -64.831
Income Available to Common Excl. Extra. Items 15.532 94.902 17.234 -39.277 -64.831
Income Available to Common Incl. Extra. Items 15.532 94.902 17.234 -39.277 -64.831
Diluted Net Income 15.532 94.902 17.234 -39.277 -64.831
Diluted Weighted Average Shares 132.383 133.663 111.361 92.8404 69.3185
Diluted EPS Excluding Extraordinary Items 0.11733 0.71001 0.15476 -0.42306 -0.93526
Diluted Normalized EPS 0.13045 0.74204 0.14058 -0.41002 -0.91562
Interest Income (Expense), Net Non-Operating -2.009 -7.236 -11.279 -6.856 -11.258
Total Adjustments to Net Income 0 0 -0.568
Cost of Revenue, Total 105.019 114.199 87.319 75.948 68.808
Gross Profit 345.874 353.86 250.979 185.033 124.641
Research & Development 39.762 30.742 20.086 14.799 10.742
Interest Expense (Income) - Net Operating 3.494
Unusual Expense (Income) 0 1.883 -2.246 1.862 2.095
Other, Net -0.013 -0.013 0.097 0.013 0.162
Minority Interest 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 117.316 107.642 115.516 116.859 121.401
Revenue 117.316 107.642 115.516 116.859 121.401
Cost of Revenue, Total 26.316 26.607 27.11 26.177 26.652
Gross Profit 91 81.035 88.406 90.682 94.749
Total Operating Expense 107.571 111.643 106.798 115.08 109.466
Selling/General/Admin. Expenses, Total 70.443 73.834 68.293 79.328 72.609
Research & Development 10.938 11.202 11.395 9.575 10.205
Unusual Expense (Income) -0.126 0 0
Operating Income 9.745 -4.001 8.718 1.779 11.935
Interest Income (Expense), Net Non-Operating -0.594 -0.649 0.03 -0.572 -0.73
Other, Net 0.028 0.023 0.006 0.005 -0.021
Net Income Before Taxes 9.179 -4.627 8.754 1.212 11.184
Net Income After Taxes 5.316 -2.969 7.486 0.215 8.744
Net Income Before Extra. Items 5.316 -2.969 7.486 0.215 8.744
Net Income 5.316 -2.969 7.486 0.215 8.744
Income Available to Common Excl. Extra. Items 5.316 -2.969 7.486 0.215 8.744
Income Available to Common Incl. Extra. Items 5.316 -2.969 7.486 0.215 8.744
Diluted Net Income 5.316 -2.969 7.486 0.215 8.744
Diluted Weighted Average Shares 133.066 131.084 131.867 132.233 132.601
Diluted EPS Excluding Extraordinary Items 0.03995 -0.02265 0.05677 0.00163 0.06594
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.0394 -0.01319 0.06163 0.00463 0.06973
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 222.609 226.979 174.344 125.6 71.131
Cash and Short Term Investments 102.478 113.929 84.394 60.174 21.291
Cash 102.478 113.929 84.394 60.174 21.291
Prepaid Expenses 5.086 4.969 4.935 2.953 2.328
Total Assets 449.359 443.259 294.494 220.687 163.678
Other Long Term Assets, Total 31.534 33.531 0.688 1.011 0.817
Total Current Liabilities 75.023 82.005 68.217 59.894 66.388
Accrued Expenses 38.155 48.374 23.973 23.45
Notes Payable/Short Term Debt 0 0 0 0 2.545
Other Current Liabilities, Total 0 1.436 0.578 5 37.177
Total Liabilities 183.69 201.224 148.41 165.104 116.637
Total Long Term Debt 66.231 70.769 64.486 97.549 49.216
Other Liabilities, Total 42.436 48.45 15.707 7.661 1.033
Total Equity 265.669 242.035 146.084 55.583 47.041
Common Stock 0.013 0.013 0.013 0.01 0.009
Additional Paid-In Capital 310.957 302.155 299.129 226.58 177.272
Retained Earnings (Accumulated Deficit) -45.301 -60.133 -153.058 -171.007 -130.24
Total Liabilities & Shareholders’ Equity 449.359 443.259 294.494 220.687 163.678
Total Common Shares Outstanding 130.919 128.68 127.732 104.871 91.2614
Preferred Stock - Non Redeemable, Net 0
Total Receivables, Net 89.45 82.46 56.804 39.359 34.077
Accounts Receivable - Trade, Net 89.45 82.46 56.804 39.359 34.077
Total Inventory 24.783 25.022 27.799 22.918 13.321
Other Current Assets, Total 0.812 0.599 0.412 0.196 0.114
Property/Plant/Equipment, Total - Net 145.655 128.304 60.068 47.184 39.623
Goodwill, Net 28.772 28.772 28.772 25.539 25.539
Intangibles, Net 20.789 25.673 30.622 20.797 26.091
Note Receivable - Long Term 0 0.556 0.477
Accounts Payable 32.33 29.339 23.381 28.387 19.165
Current Port. of LT Debt/Capital Leases 4.538 2.856 20.285 3.057 7.501
Long Term Debt 66.231 70.769 53.044 83.118 39.062
Capital Lease Obligations 0 11.442 14.431 10.154
Property/Plant/Equipment, Total - Gross 208.453 186.033 129.589 112.996
Accumulated Depreciation, Total -62.798 -57.729 -69.521 -65.812
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 225.573 216.435 216.822 222.609 230.526
Cash and Short Term Investments 98.226 88.917 88.694 102.478 107.25
Cash 98.226 88.917 88.694 102.478 107.25
Total Receivables, Net 89.276 93.615 92.021 89.45 93.115
Accounts Receivable - Trade, Net 89.276 93.615 92.021 89.45 93.115
Total Inventory 27.905 25.364 25.539 24.783 24.683
Prepaid Expenses 9.567 7.948 9.847 5.086 4.707
Other Current Assets, Total 0.599 0.591 0.721 0.812 0.771
Total Assets 462.647 450.313 446.107 449.359 457.272
Property/Plant/Equipment, Total - Net 159.866 155.369 149.476 145.655 142.381
Property/Plant/Equipment, Total - Gross 230.109 223.086 214.966 208.453 204.419
Accumulated Depreciation, Total -70.243 -67.717 -65.49 -62.798 -62.038
Goodwill, Net 28.772 28.772 28.772 28.772 28.772
Intangibles, Net 17.101 18.33 19.56 20.789 22.01
Other Long Term Assets, Total 31.335 31.407 31.477 31.534 33.583
Total Current Liabilities 81.482 73.455 76.076 75.023 89.273
Accounts Payable 26.784 27.39 30.31 32.33 37.952
Accrued Expenses 48.041 40.376 40.757 38.155 46.317
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 6.657 5.689 5.009 4.538 5.004
Other Current Liabilities, Total 0 0
Total Liabilities 185.782 179.031 182.406 183.69 200.944
Total Long Term Debt 64.283 63.891 64.86 66.231 67.6
Long Term Debt 62.117 63.489 64.86 66.231 67.6
Capital Lease Obligations 2.166 0.402
Other Liabilities, Total 40.017 41.685 41.47 42.436 44.071
Total Equity 276.865 271.282 263.701 265.669 256.328
Common Stock 0.013 0.013 0.013 0.013 0.013
Additional Paid-In Capital 317.254 314.838 312.573 310.957 309.102
Retained Earnings (Accumulated Deficit) -40.402 -43.569 -48.885 -45.301 -52.787
Total Liabilities & Shareholders’ Equity 462.647 450.313 446.107 449.359 457.272
Total Common Shares Outstanding 131.313 131.312 131.226 130.919 130.915
Preferred Stock - Non Redeemable, Net 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 15.532 94.902 17.234 -40.454 -64.831
Cash From Operating Activities 24.859 61.978 5.466 -33.528 -60.739
Changes in Working Capital -34.082 -37.71 -27.757 -9.667 -22.401
Cash From Investing Activities -33.898 -31.22 -23.498 -6.234 -1.856
Other Investing Cash Flow Items, Total 0 -5.82 0 0.001
Cash From Financing Activities -2.199 -1.036 42.468 78.727 81.642
Financing Cash Flow Items -1.256 -1.22 55.556 46.443 80.347
Issuance (Retirement) of Stock, Net 2.07 2.198 2.823 0.897 0.119
Issuance (Retirement) of Debt, Net -3.013 -2.014 -15.911 31.387 1.176
Net Change in Cash -11.238 29.722 24.436 38.965 19.047
Non-Cash Items 30.701 26.032 7.694 7.051 19.329
Cash From Operating Activities 5.845 5.781 4.438 3.388 3.309
Amortization 4.883 4.949 3.745 6.043 3.669
Deferred Taxes 1.98 -31.976 0.112 0.111 0.186
Capital Expenditures -33.898 -31.22 -17.678 -6.234 -1.857
Cash Taxes Paid 1.201 0.607 0.061 0.049
Cash Interest Paid 2.649 5.787 9.609 8.148
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -2.969 15.532 8.046 7.831 0.087
Cash From Operating Activities -5.077 24.859 17.059 11.606 1.411
Cash From Operating Activities 2.694 5.845 4.331 2.875 1.347
Amortization 1.23 4.883 3.662 2.442 1.221
Non-Cash Items 5.795 30.701 23.822 12.698 5.654
Cash Taxes Paid -0.128 1.201 -0.974 0.974 0.004
Cash Interest Paid 1.271 2.649 1.787 1.041 0.627
Changes in Working Capital -11.827 -34.082 -22.802 -14.24 -6.898
Cash From Investing Activities -7.562 -33.898 -23.242 -12.84 -6.672
Capital Expenditures -7.562 -33.898 -23.242 -12.84 -6.672
Cash From Financing Activities -1.236 -2.199 -0.324 -0.35 -0.765
Financing Cash Flow Items -0.298 -1.256 -1.256 -1.254 -0.488
Issuance (Retirement) of Stock, Net 0 2.07 2.07 2.042 0.291
Issuance (Retirement) of Debt, Net -0.938 -3.013 -1.138 -1.138 -0.568
Net Change in Cash -13.875 -11.238 -6.507 -1.584 -6.026
Other Investing Cash Flow Items, Total
Deferred Taxes 1.98
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Ades (Alan A) Individual Investor 11.6092 15244272 0 2023-04-10 LOW
Nussdorf (Glenn H) Individual Investor 11.3955 14963663 0 2023-04-10 LOW
Soleus Capital Management, L.P. Hedge Fund 8.9315 11728063 1875000 2023-06-30 HIGH
Organo PFG LLC Corporation 6.3052 8279490 0 2023-04-10 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.2627 4284292 402291 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.7617 3626444 -82649 2023-06-30 LOW
Organo Investors, L.L.C. Corporation 2.1719 2851984 0 2023-04-10 LOW
Millennium Management LLC Hedge Fund 1.6595 2179086 594812 2023-06-30 HIGH
Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.5551 2042069 633356 2023-06-30 MED
Two Sigma Investments, LP Hedge Fund 1.4891 1955304 -154104 2023-06-30 HIGH
Citadel Advisors LLC Hedge Fund 1.4174 1861190 -690700 2023-06-30 LOW
AQR Capital Management, LLC Investment Advisor/Hedge Fund 1.2763 1675933 -876280 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.1798 1549170 36435 2023-06-30 LOW
Assenagon Asset Management S.A. Investment Advisor 1.0397 1365197 0 2023-06-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.977 1282894 5594 2023-06-30 LOW
D. E. Shaw & Co., L.P. Hedge Fund 0.9679 1270965 -69878 2023-06-30 MED
Polar Asset Management Partners Inc. Hedge Fund 0.9448 1240594 1240594 2023-06-30 HIGH
ExodusPoint Capital Management, LP Hedge Fund 0.7575 994624 -25777 2023-06-30 HIGH
Marshall Wace LLP Investment Advisor/Hedge Fund 0.7109 933521 222692 2023-06-30 HIGH
Hotchkis and Wiley Capital Management, LLC Investment Advisor 0.6649 873090 31890 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Organogenesis Holdings Inc. Company profile

About Organogenesis Holdings Inc

Organogenesis Holdings Inc. is a regenerative medicine company, which is focused on the development, manufacture, and commercialization of solutions for the wound care and surgical and sports medicine markets. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.

Financial summary

BRIEF: For the nine months ended 30 September 2021,Organogenesis Holdings Inc revenues increased 47% to$339.5M. Net income totaled $43.2M vs. loss of $545K.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Basic Earnings per Share excluding Extraordinary Itemsincreased from -$0.01 to $0.34.

Industry: Biotechnology & Medical Research (NEC)

85 Dan Rd
CANTON
MASSACHUSETTS 02021-2810
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

BTC/USD

42,278.50 Price
-3.620% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

16,050.30 Price
-0.140% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.63 Price
-6.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

1,996.35 Price
-0.420% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading